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Abstract 
 
Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver 
cancer, which is the second leading cause of cancer related deaths globally and has an 
incidence of 850,000 new cases per year. The main risk factors for developing HCC are well-
known and include infection with hepatitis B and C viruses, alcohol intake and ingestion of 
the fungal metabolite aflatoxin B1. Nonetheless, knowledge is emerging regarding additional 
risk factors such as non-alcoholic steatohepatitis. Advances in the understanding of the 
molecular pathogenesis of HCC led to identification of critical driver mutations, however the 
most prevalent of these are not yet druggable targets. The molecular classification of HCC is 
not established, and the Barcelona-Clinic-Liver Cancer Classification is the main clinical 
algorithm for the stratification of patients according to prognosis and treatment allocation. 
Surveillance programmes enable detection of early-stage tumours that are amenable to 
curative therapies — resection, liver transplantation or local ablation. At more-developed 
stages, only chemoembolization (for intermediate HCC) and sorafenib (for advanced HCC) 
have shown survival benefits. There are major unmet needs in HCC management that might 
be addressed through discovery of new therapies and their combinations for use in the 
adjuvant setting and for intermediate and advanced stage disease, biomarkers for therapy 
stratification, patient-tailored strategies targeting driver mutations and/or activating 
signalling cascades and validated measurements of quality of life. Recent failures in testing 
systemic drugs for intermediate and advanced stages have pointed towards a refinement in 
trial design and defining novel approaches.  
 
[H1] Introduction  
 
Liver cancer is a major health problem, with more than 850,000 cases annually worldwide1. 
This neoplasm is currently the second leading cause of cancer-related death globally, a figure 
that is on the rise2. Among all primary liver cancers, hepatocellular carcinoma (HCC) is the 
most common neoplasm, accounting for 90% of cases1,3–12. Various risk factors for HCC 
development are well-defined, such cirrhosis (chronic liver damage caused by fibrosis), 
hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcohol abuse and 
metabolic syndrome3. Other co-factors, such as tobacco inhalation and aflatoxin B1 (a fungal 
carcinogen present in food supplies associated with mutations in the tumour suppressor 
gene TP53) intake are well-characterized contributors to HCC (Figure 1)1,3–10. Recent 
discoveries have pointed to infection with adeno-associated virus 2 (AAV2) as a novel cause 
of the disease, particularly in individuals without cirrhosis13. Primary prevention of HCC 
through HBV vaccination has been demonstrated. Similarly, in patients with chronic 
infection, effective anti-viral therapies against HBV and HCV that produce sustained 
virological responses are associated with a profound decrease in HCC incidence. Guidelines 
recommend surveillance by using ultrasonography every 6 months in at risk-populations.  
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Over the past decade, there has been an improvement in the understanding of the 
molecular pathogenesis of the disease14. Genomic analysis has provided a clear picture of 
the main drivers responsible for tumour initiation and progression. Each HCC has an average 
of 40 genomic aberrations among which few are considered drivers. Common mutations 
affect telomere maintenance (mutations in telomere reverse transcriptase (TERT)), Wnt 
pathway activation (mutations in catenin beta 1 (CTNNB1)), inactivation of cellular tumour 
antigen p53 (p53, encoded by TP53), chromatin remodelling (mutations in AT-rich 
interaction domain 1A (ARID1A)), Ras signalling, mammalian target of rapamycin (mTOR) 
signalling and oxidative stress pathway activation. Only a handful of these drivers are 
currently druggable targets, such as amplification of fibroblast growth factor 19 (FGF19).  
 
Classification of HCC is not based on the TNM system, as opposed to the majority of 
neoplasms, but on the Barcelona-Clinic-Liver Cancer (BCLC) Classification, which is endorsed 
by European and American clinical practice guidelines3,15,16. This staging system defines five 
prognostic subclasses and allocates specific treatments for each stage. Five treatments can 
extend the life expectancy of patients with HCC: surgical resection, liver transplantation, 
radiofrequency ablation, chemoembolization and the multikinase inhibitor sorafenib3. 
Around 40% of patients (early stages 0 and A) are eligible for potentially curative therapies 
— resection, transplantation or local ablation — which can provide median survival rates of 
60 months and beyond, in contrast with an historical natural history survival of 36 months. 
For patients with more-advanced disease, only two treatments have demonstrated survival 
advantages in the setting of randomized-controlled trials (RCTs). Patients at intermediate 
stage (stage B) with preserved liver function benefit from chemoembolization17,18 and have 
an estimated median survival of 26 months. Patients at advanced stage (stage C) benefit 
from systemic sorafenib, which extends survival by approximately 3 months (from 8 to 11 
months) and represents the standard of care in this setting19. During the past years, several 
studies have tested therapies in the adjuvant setting, in combination or alternatives to 
chemoembolization, and alternative systemic first-line and second-line treatments.  
 
This Primer provides an overview and up-dated summary of the current knowledge on the 
epidemiology, pathogenesis and treatment of HCC. We describe current prevention, 
evidence-based standards of care and novel therapies emerging in light of the understanding 
of the pathogenesis of HCC, such as proof-of-concept studies and immunotherapy.  
 
[H1] Epidemiology 
 
Worldwide, liver cancer is the sixth most common cancer (approximately 850,000 new cases 
each year), and the second leading cause of cancer-related deaths (approximately 800,000 
per year) (Figure 1)1,3–10. 85-90% of all primary liver cancers are HCC. Unlike other human 
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malignancies, the risk factors for HCC are well established (Table 1). Indeed, HCC is common 
in patients with advanced hepatic fibrosis or cirrhosis due to chronic liver disease, and in 
particular with liver damage caused by HBV and HCV infection and unhealthy alcohol use.  
 
The worldwide incidence of HCC and chronic viral hepatitis parallel each other. HBV is a DNA 
virus that can cause insertional mutagenesis. In the context of chronic HBV infection, HCC 
usually occurs on a background of cirrhosis (up to 85% in selected studies)20. Moreover, in 
patients with chronic HCV infection, which is caused by an RNA virus, HCC rarely occurs in 
the absence of advanced hepatic fibrosis or cirrhosis21. The highest incidence rates of HCC 
are in Asia and sub-Saharan Africa owing to the high prevalence of HBV infection (Figure 2)1. 
In Africa, aflatoxin B1 appears to be synergistic with HBV in causing HCC22. This synergy is a 
likely explanation for the earlier onset of HCC in this continent compared with the rest of the 
world. In North America, Japan and Europe, HCV is the leading cause of HCC. Other causes of 
cirrhosis associated with HCC include unhealthy alcohol use, nonalcoholic steatohepatitis 
(NASH), alpha-1 antitrypsin deficiency and hemochromatosis23. By contrast, HCC is less 
common in cirrhosis that is caused by autoimmune hepatitis, Wilson’s disease and 
cholestatic liver disorders.  
 
Along with viral hepatitis and cirrhosis, other factors can contribute to disease risk. HCC has 
a strong gender predilection, being threefold more common in men than women24 (Figure 
2)1. Most patients with HCC are over 45 years of age, except in sub-Saharan Africa, given the 
latency between the onset of virus-mediated liver inflammation and the development of 
cirrhosis. Unidentified host, viral and environmental interactions are likely responsible for 
the lower age of onset in Africa. The association between tobacco use and HCC, even in the 
presence of HBV or HCV, has been inconsistent. An emerging cause of HCC is the metabolic 
syndrome due to diabetes and obesity, and the associated liver disease nonalcoholic fatty 
liver disease (NAFLD) and NASH25. NAFLD or NASH might be — along with chronic HBV 
infection — the exception to the rule that HCC is always associated with advanced hepatic 
fibrosis or cirrhosis. A recent study that needs careful verification suggests that 
approximately 40% of patients with HCC and NAFLD or NASH might not have cirrhosis25.  
 
As discussed in greater detail below, HCC is one of the cancers for which prevention is 
possible. HBV vaccination has been shown to reduce the incidence of HCC in populations 
with a high prevalence of HBV26. Antiviral therapy for HBV with nucleotide and nucleoside 
analogues reduces, but does not eliminate, the risk of HCC in treated cohorts of patients27. 
Likewise, anti-viral therapy with interferon might reduce the risk of HCC in patients with HCV 
infection that is associated chronic liver disease28; however, this effect will need to be re-
assessed with non-interferon based direct acting antiviral drugs that are now approved for 
practice. Finally, statin use and coffee consumption are associated with a reduced risk of 
6 
 
HCC in population studies29. In the future, potent liver directed antifibrotic therapies might 
also reduce the risk of developing HCC. 
  
[H1] Mechanisms/pathophysiology 
[H2]Molecular alterations and drivers  
[H3] Early molecular alterations during hepatocarcinogenesis. 
HCC development is a complex multistep process that usually occurs in the context of liver 
cirrhosis and is related to the diversity of aetiologies of the underlying liver disease. The 
natural history of HCC in cirrhosis follows a sequence of events starting with the successive 
development of pre-cancerous cirrhotic nodules with low grade dysplasia, called low-grade 
dysplastic nodules (LGDN). This is followed by high-grade dysplastic nodules (HGDN) that can 
transform into early-stage HCC (stages 0 and A) and progress into more advanced HCC 
(stages B and C). Malignant transformation into HCC can originate from various cell types 
including mature hepatocyte and stem or progenitor cells30.  
 
Similar to other epithelial solid tumours, HCC is the result of the accumulation of somatic 
genomic alterations in passenger and driver cancer genes. As previously defined31, a cancer 
driver would be a cell-autonomous or non–cell-autonomous alteration that contributes to 
tumour evolution at any stage — including initiation, progression, metastasis and resistance 
to therapy — by promoting a variety of functions including proliferation, survival, invasion or 
immune evasion. In each HCC nodule, a mean number of 40 functional somatic alterations 
are accumulated in coding regions and consequently each tumour is the result of a unique 
combination of genetic alterations mixed together with epigenetic modifications32,33. This 
general observation underlines the complexity of hepatocarcinogenesis and the huge 
diversity of HCC (Table 2; Figure 3)33–38. However, the fact that genomic alterations are not 
accumulated randomly suggests that several pathways can cooperate to promote 
oncogenesis and that some of them can be related to specific risk factors33.  
 
Molecular markers identified to discriminate early-stage HCC from the pre-cancerous 
nodules (LGDN and HGDN) have provided some clues about the early steps of carcinogenesis 
that occurs in the context of cirrhosis39–43. On the basis of these markers, the mechanism of 
hepatocyte malignant transformation has been shown to include Wnt/β-catenin pathway 
activation, re-expression of fetal genes, deregulation of protein folding machinery and the 
response to oxidative stress. Moreover, several lines of evidence have shown that telomere 
maintenance and the telomerase complex that controls the nucleotide TTAGGG, a repeated 
sequence at the end of chromosomes, play a major part in initiation and promotion of HCC 
in cirrhosis44,45. First, mice deficient of telomerase RNA component (Terc), which codes for 
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the catalytic unit of the telomerase complex, showed short telomeres and developed 
cirrhosis followed by HCC46. Second, constitutive inactivating mutations in TERT, which 
encodes the telomerase reverse transcriptase, are associated with an increased risk of 
cirrhosis in humans47–49. However, progression to HCC involves a second step, with 
telomerase reactivation required to promote liver carcinogenesis and to allow uncontrolled 
hepatocyte proliferation (the ‘telomerase switch’)46,50. In humans, TERT is not expressed in 
normal hepatocytes, but becomes re-expressed early during hepatocarcinogenesis in LGDN 
and particularly HGDN42,51. In these lesions, telomerase re-expression is related to the 
occurrence of point mutations at two hotspots in the TERT promoter. These alterations are 
the most frequent recurrent somatic mutations identified in LGDN (6%), HGDN (20 %) and 
HCC (60%)(Figure 3)33–38. Together, these results suggest that TERT promoter mutations are 
oncogenic and, in most cases of HCC (>90%), telomerase activation is selected during 
malignant transformation and tumour progression in cirrhotic and non-cirrhotic livers34,37. 
Within this paradigm, TERT promoter activation is required at an early step of 
transformation in order to bypass the replicative senescence of cirrhotic hepatocytes. By 
contrast, acquisition of genomic diversity appears to be a late event in liver carcinogenesis14. 
 
Viral infections by HCV and HBV are also associated with early molecular alterations involved 
in malignant transformation through the induction of chronic inflammation, the expression 
of viral proteins and the viral life cycle52,53 (Figure 3)33–38. Specific molecular alterations are 
frequently related to HBV infection that can induce mutagenesis by insertion of viral DNA 
into major driver genes of hepatocarcinogenesis54. The most frequent insertions of HBV DNA 
in hepatocytes occur within the TERT promoter and activate telomerase and other 
oncogenes including lysine (K)-specific methyltransferase 2B (KMT2B, also called MLL4), 
cyclin E1 (CCNE1) and SUMO1/sentrin specific peptidase 5 (SENP5)55. In cooperation with 
HBV infection, exposure to aflatoxin B1 , which is common in subtropical regions, induces 
DNA adducts and the occurrence of frequent mutations, in particular within TP53, that have 
a specific nucleotide signature22,33. Recently, deep sequencing analysis revealed another 
DNA virus — AAV2 — that is related to a frequent harmless infection in the general 
population and causes insertional mutagenesis in rare cases of HCC13. AAV2 insertions were 
mainly identified in HCC that had developed in normal liver tissues, without other classical 
risk factors. Viral insertions are found within normal and cancerous cells, and in the tumour 
genome normally occur within typical oncogenes such as TERT, cyclin A2 (CCNA2), CCNE1, 
tumour necrosis factor superfamily member 10 (TNFSF10) and KMT2B.  
 
[H3] Cancer drivers in progressed HCC. 
 
8 
 
Several pathways and processes have been implicated in HCC progression (Table 2). First, 
telomere maintenance contributes to the evasion of cellular senescence. As previously 
mentioned, telomerase is overexpressed in 90% of HCC and this is overexpression is related 
to TERT promoter mutations in 60% of cases and to gene amplification in 5% of the 
cases33,34,38. The two hotspots of mutations are located at nucleotide positions -124 and -146 
upstream of the ATG. Mutations at both sites can create a new binding site recognized by a 
transcription factor inducing TERT mRNA expression.  
Second, the Wnt/β-catenin pathway is frequently activated in HCC through CTNNB1 
mutations that activate β-catenin (11-37% HCC cases), particularly in patients without HBV 
infection and well-differentiated tumours56,57. Inactivating mutations or deletions are also 
frequently identified in axin 1 (AXIN1, 10% of HCC cases) or more rarely in adenomatous 
polyposis coli (APC, 1-2% of HCCs) and zinc and ring finger 3 (ZNRF3, 3% of HCCs). All of these 
mutations result in activation of the Wnt/β-catenin pathway33,38.  
Third, inactivation of p53 and alterations of cell cycle are major defects in HCC, particularly in 
cases related to HBV infection. In this context, TP53 mutations are the most frequent 
alterations with a specific hotspot of mutation (R249S) in patients with aflatoxin B1 
exposure22,33,38,58. Inactivation of the retinoblastoma pathway is also frequently observed 
through retinoblastoma 1 (RB1) mutations (3-8% of HCCs) or cyclin-dependent kinase 
inhibitor 2A deletions (CDKN2A, 2-12% of HCCs). Most of these molecular defects are 
associated with poor prognosis and could contribute to a more-aggressive phenotype33,35,59.  
 
Fourth, chromatin remodelling complexes and epigenetic regulators are frequently altered in 
HCC. These alterations include mutations in the BRG1- or HRBM-associated factors (BAF) and 
polybromo-associated BAF (PBAF) chromatin complex (ARID1A mutations in 4-17% of cases 
and ARID2 mutation in 3-18% of cases) or in the histone methylation writer family (KMT2 –
MLL genes mutated in 2-4% of cases), which can also be modified by HBV insertions in 
KMT2B (MLL4) (10% of cases)33,38,55. Recently, H3K9 modifier histone-lysine N-
methyltransferase SETDB1 was identified as over-expressed in HCC60,61. SETDB1 over-
expression promotes cancer cell growth via p53 methylation and is associated with tumour 
aggressiveness and poor prognosis. Interestingly, DNA methylation is globally altered in HCC 
and aberrant modifications are associated with prognosis62 or HBV infection63.  
 
Fifth, the Ras/Raf/MAP and the PI3K/AKT-mTOR pathways are frequently activated in HCC. 
These changes are caused by amplification a region that includes fibroblast growth factor 3 
(FGF3), FGF4 and FGF19 in approximately 5% of tumours, and can also be related to 
inactivating mutations in tuberous sclerosis 1 (TSC1) or TSC2 (3-8% of cases), or in 
phosphatase and tensin homolog (PTEN) (1-3% of cases). Ribosomal protein S6 kinase, 
90kDa, polypeptide 3 (RPS6KA3) mutations that cause inactivation of ribosomal protein S6 
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kinase alpha-3 (also called RSK2) (5-9% cases) lead to an activation of ras/MAPK 
signalling32,33, whereas mutations that activate Ras proteins themselves (KRAS, HRAS, NRAS 
of BRAF) are rarely identified (<1% of cases). However, additional mechanisms of pathway 
activation remain to be identified.  
 
Finally, the oxidative stress pathway is constitutively activated in HCC owing to mutations 
that activate nuclear factor erythroid 2-related factor 2 (NFE2L2) or that inactivate kelch-like 
ECH-associated protein 1 (KEAP1) in 5-15% of HCC cases. Interestingly, these observations 
suggest that NFE2L2 can protect from HCC occurrence during the development of chronic 
liver disease but its constitutive activation can also contribute to tumour progression at a 
late stage of tumour progression32,64.  
 
DNA amplifications are also associated with HCC. The most common high-level 
amplifications in HCC are in chromosome regions 11q13 and 6p21 (5–10% of cases)32,35,65,66. 
Cyclin D1 (CCND1) and FGF19 are bona fide oncogenes in 11q13 and represent potential 
therapeutic targets66. Similarly, high-level gains of 6p21 that contain more than four copies 
of vascular endothelial growth factor A (VEGFA) have been identified in 4–8% of HCC cases65. 
VEGFA amplification induces both neoangiogenesis and tumour proliferation resulting from 
the induction of macrophage-mediated hepatocyte growth factor secretion67. Whether 
these amplifications represent targetable oncogenic addiction loops in HCC remains to be 
elucidated by the testing of selective molecules in clinical trials. 
 
Modelling of HCC development in mice is a very useful approach for achieving better 
understanding of the mechanisms of hepatocarcinogenesis and for testing for new 
therapies. For drug screening, HCC cell lines or primary tumours xenografted in immuno-
deficient mice are easy to test for drug response. In more sophisticated models, candidate 
oncogenes or tumour suppressor genes can be genetically modified in classical transgenic or 
knockout animal models. More recently, siRNA68 and CRISPR/Cas969 techniques have 
emerged as powerful methods to generate tumours in mice and to subsequently test for 
drug response. 
  
[H2] Molecular classes  
 
Genomic studies have revealed molecular subclasses of HCC (reviewed in14)65,70–73. Two main 
molecular classes, each representing approximately 50% of patients, have been identified: 
proliferative and non-proliferative HCC65,71,73. The proliferative subclass is enriched by 
activation of Ras, mTOR, and insulin-like growth factor (IGF) signalling and FGF19 
amplification, and is associated with HBV-related aetiologies and poor outcomes65,71,72,74. 
Some authors have proposed that there are two subtypes of the proliferative class: the 
Wnt/transforming growth factor β (TGF-β) group and the progenitor-cell group. The 
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progenitor cell group is enriched in progenitor cell markers, such as epithelial cell adhesion 
molecule (EpCAM), and the overexpression of α-fetoprotein65,71,72,74,75. By contrast, the non-
proliferative subclass is more heterogeneous, but there is still a clear subtype characterized 
by CTNNB1 mutations that are associated with alcohol-related and HCV-related HCCs75. 
Direct translation of molecular HCC subclasses into clinical management is yet to be 
achieved.  
 
 
[H2] Role of the microenvironment  
[H3] Chronic inflammation.  
An altered microenvironment is now perceived to be a key enabling characteristic of cancer 
and is known to participate in all stages of malignant progression, from the initial 
transformation phases, through invasion and all the way to metastasis76,77. Pathologists have 
long recognized that some tumours are densely infiltrated by cells of both the innate and 
adaptive arms of the immune system and thereby mirror inflammatory conditions arising in 
non-neoplastic tissues76,78. HCC is a prototypical inflammation associated cancer, with 
approximately 90% of HCC burden associated with prolonged hepatitis due to viral hepatitis, 
excessive alcohol intake or NAFLD-NASH. This indicates that the immune microenvironment 
plays pivotal parts in the pathogenesis of this disease79. Interestingly, in fully developed 
HCCs, the presence of immune infiltrates is associated with a better prognosis, likely owing 
to more effective anti- tumour immunity80. Remarkably, an unbiased screen of gene 
expression patterns in HCC revealed that activation of the key innate inflammatory signalling 
mediators nuclear factor of κ light polypeptide gene enhancer in B-cells (NF-κB), epidermal 
growth factor (EGF) and interleukin-6 (IL6) in the liver parenchyma, but not in tumour cells, 
is associated with poor prognosis81. Furthermore, as noted above, genomic screens of HCC 
also did not reveal mutations that activate inflammatory signalling pathways. Thus, it seems 
that the inflamed liver promotes the seminal HCC cells at early phases of development82.  
 
Multiple cell types interact with hepatocytes in the chronically inflamed liver. These include 
among others macrophages, stellate cells, endothelial cells and lymphocytes; all of which 
were shown in certain mouse models to favour tumour growth. Importantly, although the 
liver is envisaged as a metabolic organ, it maintains a uniquely tolerant immune system, 
which his necessary to prevent the induction of immunity against multiple antigens and 
immunostimulatory molecules, such as gut-derived nutrients and microbiota derived signals 
which constantly flood the liver via the portal system. Understanding this unique hepatic 
immune system is likely important in the context of the complex interaction between 
malignant hepatocytes and the liver immune system83,84. 
 
11 
 
The mechanisms through which immune cells promote growth of early-stage HCC are 
beginning to be elucidated. Multiple experimental models have substantiated that secretion 
of various cytokines by immune cells can change function of the interacting hepatocyte, 
rendering it less sensitive to intracellular tumour suppressor pathways (and possibly also to 
extracellular ones such as anti-tumour adaptive immune responses). An example is secretion 
of TNF by macrophages in the chronic inflammatory hepatic infiltrate, which activates the 
NF-κB pathway in hepatocytes, rendering the latter less sensitive to apoptosis and thus 
promoting carcinogenesis85.Two important inflammatory signalling pathways that are 
activated by inflammatory cytokines in chronically inflamed livers and promote HCC are the 
NF-κB and JAK-STAT pathways86. Similarly, multiple molecules that are secreted by 
microenvironmental constituents have been shown to promote hepatocyte growth; these 
include TNF, lymphotoxin-α, lymphotoxin-β86, IL-687 and hepatocyte growth factor (HGF)88. 
The ability of inflammatory cells to produce potentially mutagenic reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) is considered by many to underlie some of their 
pro- tumourigenic activity89; yet this must still be substantiated by rigorous testing in animal 
models. However, it is clear that the increased hepatocyte proliferation that occurs in 
chronic hepatitis can potentiate DNA damage induced mutations90.  
 
[H3] Fibrosis.  
Hepatic stellate cells normally reside in the liver sinusoids and have multiple roles in hepatic 
homeostasis including retinoid storage, immunomodulation, liver regeneration and 
vasoregulation. Importantly, upon liver injury they are the primary cellular mediators of 
hepatic fibrosis and cirrhosis, which are strongly associated with HCC79. The presence of a 
stellate cell gene expression signature is a poor prognosis indicator in human HCC91 and 
overexpression of platelet-derived growth factor C (PDGFC) in the mouse liver induces 
stellate cell activation and hepatic fibrosis followed by HCC92. Taken together, these data 
indicate that hepatic fibrosis and cirrhosis have a causative role in HCC. The mechanisms 
through which activated stellate cells could drive HCC progression include cytokine 
secretion, angiogenesis promotion, protumorigenic extracellular matrix components, 
increased tissue stiffness and immunosuppression; yet the human relevance of each of these 
mechanisms and its relative contribution remain to be elucidated93. In summary, chronic 
liver inflammation generates a pathologic microenvironment, infiltrated by adaptive and 
innate immune cells and stellate cells, together producing a pathological milieu composed of 
collagen, multiple extracellular matrix proteins, growth factors and cytokines which can form 
a protumorigenic stroma. 
 
[H3] Targeting the microenvironment in HCC.  
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Because the tumour microenvironment plays a pivotal part in the natural history of HCC, 
there is a strong rationale for modulating the dynamic cross talk between hepatocytes and 
the stroma as treatment for this disease79, in particular in HCC prevention. Reversing liver 
fibrosis is already feasible in patients with chronic liver disease using antifibrotic therapies94. 
Conceivably, targeting various immune cells is also achievable, as is the targeting of specific 
molecules which are present in the pro tumourigenic hepatic microenvironment. Despite 
these possibilities, improved knowledge of the relative contribution of the different cells and 
molecules composing the chronically inflamed hepatic network to HCC pathogenesis, and 
elucidation of the network's hierarchy, is needed for planning potent preventive or 
therapeutic schemes. Such developments will entail better understanding of the complex 
natures of the interactions that take place in chronically inflamed human livers, in concert 
with meticulous testing of their functional relevance in animal models recapitulating the 
different aetiologies of hepatic inflammation (viral, metabolic and other). The ideal 
preventive treatment should convert a pro-tumourigenic microenvironment into an anti-
tumourigenic one.  
 
[H1] Diagnosis, screening and prevention  
[H2] Prevention 
[H3] Vaccination. 
The most effective approach for preventing HCC is prevention of the underlying liver disease, 
the best example of which is hepatitis B vaccination. Universal vaccination against hepatitis B 
would be expected to reduce HCC incidence, and this has indeed been demonstrated26,95. 
The first evidence of the ability of the HBV vaccine to reduce the incidence of HCC came 
from Taiwan after the introduction of universal neonatal vaccination in 1984. This 
programme was associated with a reduction in the incidence of childhood HCC from 0.7 per 
100,000 individuals to 0.36 per 100,000 individuals between 1981 and 1994 (P<0.01)95. As 
the vaccinated cohort aged, the decrease in HCC incidence was carried through to 
adolescents and is now being detected in young adults26.  
However, there are currently approximately 400 million adults who are infected with 
hepatitis B. Not all of those with hepatitis B are at equal risk of developing HCC. Various risk 
factors are well known, including hepatitis B viral load, male sex, older age and active liver 
disease96–103. For those who have active disease and who receive treatment for hepatitis B, 
the risk of HCC is reduced, although not eliminated104. This has been demonstrated in a 
single RCT using the antiviral medication lamivudine105, a study that unfortunately did not 
have HCC incidence as an endpoint. However, similar results have now been obtained in 
cohort studies using various methods to match treated and untreated populations, including 
historical controls106.  
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Similarly, treatment and eradication of hepatitis C results in a decreased HCC incidence21. 
This has only been documented in cohort studies. There are no RCTs comparing HCC 
incidence in treated patients compared with untreated patients. Such a study would not be 
ethical. However, cohort studies have documented that the HCC incidence in those 
successfully treated for hepatitis C is lower than in historical untreated controls107–110. Until 
recently, standard treatment of hepatitis C was based on interferon, and sustained virologic 
responses in patients with hepatitis C cirrhosis have been associated with a substantial 
reduced risk in HCC development (hazard ratio (HR) 0.23, confidence interval (CI) 0.16-0.35)111. 
It is too early to ascertain the effect of new direct acting antiviral (DAA) drugs for HCV – that 
achieve sustained virological responses in 90% of cases- on the occurrence of HCC112. If one 
extrapolates from the interferon era to the current DAA therapy setting, as a greater 
proportion of individuals who are infected with HCV are treated, the overall hepatitis 
burden, and the absolute number of patients with hepatitis who become at risk for HCC, will 
decrease. However, the overall effect of DAA therapy will be modest because most 
individuals with HCV remain undiagnosed, and treatment penetrance is limited owing to 
socioeconomic factors. Assuming that one-third of patients with HCV come to medical 
attention and achieve 90% sustained virologic responses with DAA agents, the burden of 
HCC in the United Stated might be reduced by 10-15% over the next decade113,114.  
 
[H3] Chemoprevention.  
There are several putative chemopreventative agents that have been proposed to reduce 
HCC incidence in at-risk populations, including statins and metformin115. The data on 
metformin are becoming more robust, as demonstrated by a meta-analysis that suggested 
metformin decreases the risk of HCC in people with diabetes116. Moreover, a study has 
shown that metformin may be safely continued in people with diabetes who also have 
cirrhosis117. Nonetheless, the evidence for the ability of metformin to reduce HCC risk is not 
strong enough to recommend using it in at-risk patients, and prospective studies testing this 
agent are required.  
 
[H3] Lifestyle modification.  
Whether abstinence from alcohol in those with alcoholic liver disease decreases the 
incidence of HCC is not yet known. Of course, primary prevention by counselling against 
unhealthy use would reduce the incidence of alcohol associated cirrhosis and the attendant 
risk of HCC. Similarly, for those with NAFLD who successfully lose weight or otherwise 
control their disease, there is no information as to whether HCC incidence is reduced113. 
Thus, in summary, prevention of HCC in large part depends on prevention or treatment of 
the underlying liver disease. 
 
[H2] Surveillance for HCC  
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When HCC causes symptoms, the disease is most often in an advanced stage, and not 
amenable to potentially curative treatment. Death usually ensues within a few months. 
However, HCC has a prolonged sub-clinical course that provides the opportunity for early 
detection. Early-stage HCC lesions are small and frequently curable, often by minimally 
invasive methods. These considerations have led to the development of protocols for 
surveillance for HCC in patients at risk for this cancer (Table 1). Surveillance, however, 
remains controversial since the only RCT that demonstrated decreased mortality was 
probably statistically incorrectly analyzed118. Nonetheless, there is a wealth of evidence of 
lesser quality, including cohort studies with comparisons between screened and unscreened 
populations, and demonstration that cure is more likely with HCC that is detected by 
surveillance compared with cases that are diagnosed once symptoms have become 
apparent119–124. Several cost-efficacy analyses have also demonstrated benefits of 
surveillance125–137. Furthermore, in considering the potential benefits from surveillance 
compared with the potential harms it is clear that benefits outweigh harms. Benefits include 
early detection and potential cure of HCC. Harms include some additional investigations and 
potentially some unnecessary interventions. However, as discussed below, a diagnostic 
algorithm has been developed that was designed to minimize false-positives, and thereby 
reduce the likelihood of harm. More recently, there have been a number of risk scores 
developed to improve identification of the at-risk population. None have yet received 
widespread application.  
 
The techniques for surveillance are also controversial. There is no question that ultrasound 
should be part of the algorithm, but the use of biomarkers remains controversial. There is 
some suggestion that biomarkers improve early detection138–144, but there is as yet no 
evidence that this leads to improved cure rates compared with ultrasound alone. Most 
importantly, the usual serum biomarkers that are used — α-fetoprotein (AFP), des-γ 
carboxyprothrombin (DCP) and the L3 fraction of AFP (AFP-L3) — are all more frequently 
associated with advanced-stage disease than early-stage disease and would therefore be 
theoretically unsuitable for detection of early disease138–144. Among these, AFP is the most 
widely used and this still remains an area of controversy.  
 
The ideal surveillance interval for at-risk patients (Table 1) according to guidelines is 6 
months3,23,145–148. Studies have demonstrated that a 3-month interval does not enhance 
outcomes146, and survival is lower with 12 month than with 6 month intervals145.  
 
 
[H2] Diagnosis 
Patients enrolled in a surveillance programme are diagnosed by identification of a new liver 
nodule on abdominal ultrasound, and diagnostic confirmation using either non-invasive 
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criteria or biopsy. These patients are generally asymptomatic and have early stage HCC. 
Conversely, patients diagnosed outside surveillance usually present at advanced stages with 
large symptomatic tumours and/or portal vein invasion. Symptoms include malaise, weight 
loss, anorexia, abdominal discomfort or signs related to advanced liver dysfunction. 
Diagnosis can be made by non-invasive (radiological) or invasive (biopsy) approaches. 
Radiological diagnosis is achieved with a high degree of confidence if the lesion is found in a 
patient with cirrhosis. Using contrast imaging, the lesion shows the radiological hallmarks of 
HCC, which are hypervascularity in the arterial phase of a contrast study (CT or MRI) and a 
decreased signal compared with the rest of the liver in the venous and/or delayed phases of 
the study149. When these typical features are observed the diagnosis is confirmed and a 
biopsy is not necessary3,15,150,151. Latest generation CT and/or MRI following reported 
protocols are recommended152. MRI with liver specific contrast agents might help in the 
diagnosis of HCC, but the specificity of these agents is still suboptimal.  
 
The caveat of the non-invasive radiological criteria is that this algorithm only applies to those 
who have an elevated risk of HCC. A biopsy is required for patients who do not have any 
special risks for HCC, for the most part patients without cirrhosis. The recommended 
algorithm for investigation of lesions in at-risk patients is as follows3,15: For nodules < 1 cm in 
size, ultrasound follow-up at 3 months is recommended. For lesions > 1 cm, the radiological 
hallmarks of HCC define diagnosis. If the radiology is not typical in at least one of two 
imaging techniques (CT and MRI), a liver biopsy is recommended3,15. Of note, this accepted 
practice puts the assessment of HCC at a disadvantage compared with most cancers since 
tumour tissue for molecular studies would not be routinely obtained in clinical practice. 
Recent guidelines recommend obtaining tissue samples in the setting of all research studies 
in HCC3. 
 
Diagnostic difficulty occurs mainly with early-stage HCC lesions, in which the radiological 
appearance might be atypical, necessitating a biopsy. However, biopsy is not an ideal gold 
standard, because of variation introduced by sampling and complications. The risk of 
complications, such as tumour seeding and bleeding, after liver biopsy is less than 3%153. 
Although the sensitivity of liver biopsies ranges between 70-90% for all tumour sizes3, small 
lesions might be missed, giving a false-negative result. In addition, in early-stage HCC, 
morphological changes may be minimal compared with dysplastic hepatocytes, making the 
diagnosis uncertain154. In this setting, the use of special stains may help to resolve diagnostic 
uncertainties. For example, HCC cells expresses glypican 3, glutamine synthetase, heat shock 
protein 70 and clathrin heavy chain155–157. Positive staining for two of these four markers is 
highly specific for HCC. In addition, comparison of the tumour biopsy to biopsy of the 
surrounding non-tumourous liver may be helpful in highlighting the early features of 
malignancy. Patients with suspicious lesions in whom a diagnosis cannot be confirmed on a 
biopsy should be closely monitored, and might even require a second biopsy.  
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[H1] Management  
[H2] Overview of evidence-based management and staging systems  
 
The BCLC staging system provides an easy-to-use algorithm that links tumour stages with 
treatment allocation policies based on evidence (Figure 4)3,158,159. Treatments are classified 
as radical therapies with potential to cure HCC — such as surgical resection, liver 
transplantation or percutaneous ablation — or palliative therapies which are aimed at 
improving survival —chemoembolization and sorafenib3. Treatment allocation for standard 
of care follows the levels of evidence defined by the National Cancer Institute, which rely on 
strengths of study design and end points (Table 3). Controversy regarding HCC staging 
systems remains. In fact, alternative staging or scoring systems have been proposed, such as 
the Hong Kong classification160, the Cancer of the Liver Italian Program (CLIP) score161, the 
TNM system162 and the Japan Integrated Staging (JIS) score163. None of these systems has 
acquired global consensus. Scoring systems, such as the CLIP, are not widely use since they 
do not incorporate treatment allocation to distinct prognostic stages, whereas others are 
specifically applied in Asia (the Hong Kong system and the JIS).  
 
[H3] Early-stage disease. 
Surgical resection is the first-line option for patients with early-stage HCC (BCLC 0 or A) with 
solitary tumours, and confers 5-year survival rates of 70%3,15,164,165. Introduction of 
restrictive selection of candidates for resection — patients with single nodules, absence of 
portal hypertension and well-preserved liver function — along with anatomic resection — in 
which tissue removal is performed in-line with the location of functional segments of the 
liver — has minimized complications and reduced recurrence3,15,164,166. Metastases and de 
novo HCC account for 70% 5-year recurrence after resection 167, and no adjuvant therapies 
are able to prevent this complication168. Adoptive immunotherapy169 and the vitamin A 
derivatives acyclic retinoids170 were reported as effective treatments in this setting; 
however, these trials were conducted in small study populations and the results have not 
been reproduced.  
 
Liver transplantation is the best first-line option for patients with tumours within Milan 
criteria (defined as a single tumour <5 cm in size or three nodules <3 cm in size without 
vascular invasion) (BCLC A) that are unsuitable for resection3,171. These criteria have been 
independently validated internationally and have been adopted by guidelines3,15,165 and Liver 
Transplant Units. Nonetheless, some studies have pointed to the fact that moderate 
expansion of Milan criteria might lead to acceptable and competitive long-term 
outcomes172–174. Local ablation using radiofrequency has been proposed as an optimal 
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alternative to resection in patients with a single tumour of <2 cm in size who are unsuitable 
for transplantation16,175, but no RCTs specifically addressing this issue have been reported. 
On the other hand, in patients with early tumours (BCLC 0 or A) who are not suitable for 
surgery, local ablation is the standard of care with 5-year survival rates of 50–70%3. 
 
[H3] Intermediate-stage disease.  
Patients with intermediate-stage HCC (BCLC B) are characterized by multinodular disease, 
preserved liver function and the absence of tumour-related symptoms, vascular invasion and 
extrahepatic spread. Chemoembolization in the form of transcatheter arterial 
chemoembolization (TACE) — a minimally invasive technique that combines local delivery of 
beads to restrict tumour blood supply with local administration of chemotherapy — is 
recommended based on results from RCTs and one meta-analysis of pooled data17,18,176. 
Improvements in the selection of candidates, supra-selective embolization – selective 
blockade of the artery feeding the tumour that minimizes collateral hepatic toxicity — and 
improvements in embolization devices (drug-eluting beads) have led to current median 
survival times of 26 months177, and beyond 40 months in referral centres178. Alternative 
embolization strategies, such as radioembolization using beads coated with yttrium-90 (Y-
90) — an isotope that emits short-range β radiation — are effective and have a favourable 
safety profile179, but only well-designed, properly powered RCTs will determine the 
therapeutic niche of this intervention.  
 
[H3] Advanced and end-stage disease.  
The Sorafenib HCC Assessment Randomized Protocol (SHARP) trial demonstrated that 
sorafenib, a multiple tyrosine kinase inhibitor, was able to substantially increase survival in 
patients with advanced-stage HCC (BCLC C) from 7.9 months to 10.7 months (HR 0.69)19. The 
beneficial effects of sorafenib occur regardless of HCC aetiology, as was validated in Asian 
patients who were infected with HBV180. On the basis of these data, sorafenib became the 
standard of care in this setting. Eight RCTs testing alternative systemic molecular treatments 
reported since the SHARP trial have not shown survival benefits in HCC. These findings can 
be partially explained by the specific toxicity of some agents owing to the underlying liver 
cirrhosis, the high molecular heterogeneity of HCC and a relative resistance to conventional 
chemotherapy181. Patients with end-stage disease (BCLC D) should be considered for 
nutritional and psychological support and proper management of pain, but are not 
candidates for entering clinical trials. 
 
[H2] Surgical therapies  
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Surgery is the treatment of choice for most patients with early-stage HCC, with 5-year 
survival in appropriately selected cases exceeding 70%; its role in more-advanced HCC is 
more controversial3,165. The large majority of patients with HCC have underlying liver 
disease, and both the location and extent of the tumour and the status of the non-malignant 
tumour liver tissue must be considered in the choice of surgical procedure. The prognosis of 
chronic liver disease is commonly assessed using the Child-Pugh score, which uses five 
clinical measures — total bilirubin, serum albumin, prothrombin time, ascites severity and 
hepatic encephalopathy grade — to classify patients into one of three groups (A-C) of 
predicted survival rates. In brief, Child-Pugh’s A reflects well-preserved liver function, Child’s 
B moderate liver dysfunction with a median life expectancy of approximately 3 years and 
Child C severe liver dysfunction with life expectancy of approximately 1 year182. 
 
[H3] Resection.  
Patients with a single technically resectable HCC without macrovascular invasion, with 
preserved liver function (Child-Pugh class A with bilirubin < 1 mg per dl) and no portal 
hypertension are optimal candidates for partial hepatectomy, and experience low (1-2%) 
perioperative mortality15,164–166(Table 3; Figure 4)3,158,159. Limited, yet anatomical, resection 
is preferred when possible in order to spare uninvolved liver parenchyma and to remove 
satellite tumours that result from local vascular invasion183; when major (≥ 3 segment) 
resection is required, preliminary portal embolization184 or lobar radioembolization185 is 
performed in some centres to induce growth of the future liver remnant. Over a period of 4-
6 weeks following portal embolization, the volume of the contralateral liver lobe typically 
increases by 20-25%, thereby decreasing the risk of postoperative hepatic insufficiency. 
These practical approaches have not yet been adopted by guidelines. With improving 
technology and experience, laparoscopic resection is increasingly employed with improved 
early outcomes186, and percutaneous thermal ablation has become an acceptable alternative 
for accessible tumours < 2cm175. Resection is often applied outside of guidelines for patients 
with multifocal HCC or portal hypertension, particularly in Asia where availability of 
transplantation is limited, albeit with decreased 5-year survival (50-60% compared with > 
70% in optimal candidates)187.  
 
Recurrence of HCC in the liver is common after resection (up to 70% at 5 years)165,188, 
because the remaining liver is both the most common site of metastasis of the primary HCC, 
and is at risk for developing de novo HCC. With careful follow-up, recurrence can often be 
treated effectively by repeat resection189, thermal ablation or liver transplantation190 with 
resultant long-term survival. There is no proven adjuvant therapy for HCC resection; small 
trials have produced positive results for retinoids170, immunotherapy169 and I-131 lipiodol191, 
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but these have not been confirmed in larger studies, and a large RCT including more than 
1000 patients of sorafenib in this setting showed no benefit168.  
 
[H3] Transplantation.  
Liver transplantation is indicated for patients with early-stage HCC who fall within Milan 
criteria and who are not candidates for partial hepatectomy3,15,171. For these patients, 
transplantation yields a 5-year survival rate of 70% with a recurrence rate of approximately 
10%, and 10-year survival rates > 50%192(Table 3; Figure 4)3,158,159. Transplantation offers the 
appeal of removing unrecognized intrahepatic metastases and essentially eliminating the 
risk of de novo tumour development, but this benefit is offset by higher perioperative and 
late non- tumour-related mortality such that post-transplant survival, at least to 5 years, is 
not substantially better than after resection188. Donor organ scarcity varies geographically. 
To the extent that patients must wait for organs, drop-out from the waiting list owing to 
tumour progression reduces transplant survival on an intention-to-treat basis166, and loco-
regional treatment to prevent progression while waiting is an integral part of the process193 . 
Living donor transplantation is a way for patients with suitable donors to avoid the risk of 
waiting list drop-out; results are comparable to those achieved with deceased donors194. The 
mTOR inhibitors sirolimus or everolimus are often added to the immunosuppressive 
regimen195. However, their effectiveness as anti-tumour therapies to prevent recurrence-
free-survival after transplantation failed in a recent RCT196,197. 
 
The Milan criteria are widely used as the basis for transplant eligibility, and adherence to 
them yields good post-transplant survival. Increasingly, however, the benefit provided by 
transplant compared with the alternatives (for example, resection and loco-regional 
therapies), as opposed to the absolute survival rate, is being considered in discussions about 
donor organ allocation; basing allocation on benefit of transplant rather than on absolute 
survival could lead to different choices of transplant candidates. For example, the benefit of 
transplant for a patient with single HCC within Milan criteria as compared with resection 
may be considerably less than the benefit of transplant for multinodular HCC beyond Milan 
criteria as compared to chemoembolization, even though the absolute survival after 
transplantation in the second scenario is lower198. Several cohorts have explored the 
implication of extending Milan criteria for transplantation in HCC199. Extended criteria such 
as the University of California San Francisco (UCSF)200 and Up-to-7172 proposals have been 
reported to yield survival rates similar to the Milan criteria, as has down-staging of HCC 
beyond the Milan criteria by loco-regional treatment201. Selection criteria for extended 
indications based on genomic information have reported good outcomes175. The 
reproducibility of these proposals on a large scale awaits confirmation. 
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Postsurgical outcomes are dependent on the nature of the underlying liver disease. 
Historically, results have been better in HBV-related HCC compared with HCV-related HCC188 
because viral control has been possible for HBV, leading some authors to propose more 
liberal surgical guidelines for patients with HBV-related HCC160.There is good reason to 
expect that with the recent development of effective HCV treatment202, improved results of 
both resection and transplant might lead to a broadening of the accepted indications for 
surgical treatment in patients with hepatitis C.  
 
[H2] Loco-regional therapies  
[H3] Percutaneous ablation.  
Percutaneous and intraarterial therapies are usually performed by interventional radiologists 
and are the mainstay of the treatment of patients with early-stage and intermediate-stage 
HCC (BCLC 0-B) who are not candidates for surgery (Table 3). Percutaneous tumour ablation 
involves the insertion of a needle through the skin to access the inside of a tumour. This 
approach can be used to inject agents that induce tumour cell killing (usually absolute 
ethanol) or to insert a probe that delivers energy that induces a deleterious increase in 
temperature (radiofrequency, microwave or laser)203. Tumour size (≤ 3 cm), number (≤ 3 
tumours) and location (accessible with ultrasound guidance) limit the applicability of 
percutaneous ablation204.  
 
Several RCTs have demonstrated a significant benefit of radiofrequency ablation compared 
with percutaneous ethanol injection in terms of complete response rate (absence of contrast 
uptake within the treated lesion in the arterial phase of CT or MRI) and time to 
recurrence205,206. As a result, radiofrequency is the standard ablative therapy at early stages 
of the disease since it provides better results than ethanol205 (Figure 4)3,158,159. Ethanol 
injection is nevertheless a valuable option for tumours located near the large hepatic vessels 
and bile ducts, or in centers with limited access to technology. Five-year survival rates after 
radiofrequency ablation averages 60%207. Although tumour progression or relapse is higher 
after percutaneous ablation than after liver resection, the long-term outcomes are similar 
and ablation has been proposed as first-line therapy for tumours that are < 2 cm in size16. 
 
[H3] Intraarterial therapy.  
The most commonly used intraarterial therapy is TACE, which involves the sequential 
injection into one or more branches of the hepatic artery of chemotherapeutic drugs 
(doxorubicin, mitomycin C, cisplatin or combinations) loaded to the particles or emulsified in 
Lipiodol (an oily contrast agent that is selectively retained in the HCC nodules) and 
embolizing particles that interrupt blood flow208,209. The result is the induction of acute 
ischaemic necrosis and eventually a prolonged exposure of tumour cells to the drugs. TACE is 
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nowadays usually performed ‘on demand’, with patients being evaluated every 6-8 weeks 
with contrast-enhanced CT or MRI and additional selective TACE sessions performed only if 
active tumour areas are found210. The use of the more costly drug-eluting particles results in 
a simpler and more standardized procedure that increases tumour response rates but does 
not improve survival211. 
 
Strong scientific evidence makes TACE the standard of care for patients with large or 
multiple tumours (BCLC B) or those small tumours that cannot be resected or 
percutaneously ablated (BCLC A unsuitable for surgery or local ablation), if the patient has a 
preserved liver function, no cancer-related symptoms and no vascular invasion or 
extrahepatic spread3. Two RCTs 17,176 and one meta-analysis of pooled data established a 
significant benefit of TACE versus supportive care or suboptimal therapies (tamoxifen and 
oral 5--fluorouracil (5-FU) in this patient population18 (Figure 4)3,158,159. Median survival after 
TACE ranges from 16-45 months in the early stage (BCLC 0-A), 15.6-26.3 months in 
intermediate stage (BCLC B) and 6.8-13.6 in the advanced stage (BCLC C)177,212. The largest 
RCT ever reported for TACE describes a median survival duration of 26 months for patients 
with intermediate-stage HCC177. Combination strategies with TACE and systemic therapies 
(brivanib or sorafenib) have not resulted in clinical benefit177,213. A different meta-analysis 
that included the combination of different loco-regional therapies (TACE or radiofrequency 
ablation in the active arms) has questioned the benefits of TACE214. The use of TACE alone or 
in combination with sorafenib for patients with advanced-stage HCC is not supported by 
scientific evidence or recommended by guidelines3,23.  
 
Alternatives to TACE include Y90-radioembolization, which uses much smaller embolizing 
particles that are injected into the hepatic arteries to provide selective internal irradiation of 
the tumours179,215. Evidence of survival benefit for radioembolization has not yet been 
proven in the setting of RCTs compared with the standard of care, which is TACE in 
intermediate-stage HCC and sorfenib in advanced-stage HCC. This technique is usually 
applied to those patients that are not good candidates for TACE because of large tumour 
burden, vascular invasion or progression to prior TACE216. A second alternative to TACE is 
bland transarterial embolization (TAE), which involves occluding the tumour blood supply 
using microbeads without simultaneous administration of chemotherapeutic agents. TAE has 
provided lower response rates compared with TACE in RCTs217, and a meta-analysis showed 
that it provides suboptimal survival compared with TACE18. Finally, hepatic arterial infusion 
chemotherapy — a catheter-based procedure for the long-term administration of agents 
directly into the liver — is frequently used in Japan to treat patients who are poor candidates 
for TACE, however there is no scientific evidence supporting this approach. 
 
[H2] Systemic therapies and future treatment approaches  
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More than 100 RCTs have been reported testing chemotherapy or other types of systemic 
therapies in HCC, but only one drug, sorafenib, has proven survival advantages19,180,218. 
Treatment with systemic chemotherapy and anti-oestrogen therapies has been shown to be 
ineffective in HCC18. Systemic chemotherapy with doxorubicin, PIAF regime (platinum, 
interferon, doxorubicin and 5-FU)181 and FOLFOX regime219 lacked survival advantages and 
was accompanied in some instances with important toxicity. Treatment with sorafenib is 
associated with manageable adverse events (diarrhoea and skin reactions on the hands and 
feet) and an absolute increase in median survival of 3 months19. Subsequent studies 
revealed a stable benefit of this drug in all regions of the world and in all HCC aetiologies220, 
an in recent trials sorafenib consistently showed a median survival of approximately 10 
months. Unfortunately, no predictive biomarkers of responsiveness to sorafenib have been 
identified221. Although sorafenib is in a unique position of primacy in the management of 
HCC, it has some restrictions in the target population (not indicated in patients with poor 
liver function or in the adjuvant setting) and in the understanding of the mechanism of 
action. The efficacy of sorafenib probably results from a balance between targeting cancer 
cells and the microenvironment by blocking multiple kinases — up to 40, including vascular 
endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor 
(PDGFR), mast/stem cell growth factor receptor (c-Kit) and/or serine/threonine-protein 
kinase B-raf (BRAF)222. Interestingly, this wide blockade does not induce liver damage or 
other life-threatening complications.  
 
The main characteristics of the SHARP trial have been adopted by guidelines of trial design223 
and replicated by almost all subsequent studies testing molecular therapies in HCC218. This 
seminal study enrolled patients with well-preserved liver function (as indicated by Child-
Pugh A class), with advanced disease (BCLC C) or those with intermediate stage disease 
(BCLC B) that progressed following TACE, and defined overall survival as the primary end 
point (Table 5). Nonetheless, none of the therapies tested after the SHARP trial, including 
brivanib (a fibroblast growth factor receptor (FGFR) and VEGFR inhibitor)224, sunitinib (a c-
Kit, VEGFR and PDGFR inhibitor)225, linifanib (a VEGFR and PDGFR inhibitor)226, erlotinib (an 
epidermal growth factor receptor (EGFR) inhibitor)227 in the first line-setting and brivanib228, 
everolimus (an mTOR inhibitor)229 and ramucirumab (a VEGFR2 inhibitor)230 in the second-
line setting have demonstrated survival benefits in patients with HCC. The reasons for the 
disappointing Phase III clinical trial results are reviewed elsewhere231 and include a marginal 
anti-tumour potency, liver toxicity, flaws in trial design and lack of biomarker-based 
enrichment. Randomized Phase II studies are recommended prior to conducting pivotal 
Phase III trials. Phase II studies are essential for identifying signals of efficacy, futility or 
toxicity, and might prevent the devotion of resources to Phase III trials that test therapies 
with marginal chances of success. Overall survival is the mainstay end-point for Phase III 
studies. Although time-to-progression remains relevant in Phase II studies223, recent results 
pointing to a lack of correlation between TTP and OS225,226,228 suggest assessing 
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simultaneously other end-points such as objective response using the modified Response 
Evaluation Criteria In Solid Tumours (mRECIST)231,232. Regarding biomarkers, none of the 
Phase III studies were enriched by biomarker analysis, which could have indicated 
effectiveness of the drug in selected subpopulations.  
 
Most of the drugs currently being tested in Phase III trials are antiangiogenic agents, cell 
cycle inhibitors, receptor tyrosine kinase inhibitors and checkpoint inhibitors (Table 4; Figure 
5). These broad spectrum compounds are tested in HCC in ‘all comers’, such as levantinib (a 
VEGFR2 and VEGFR3 inhibitor) for first-line treatment and regorafenib (multikinase inhibitor, 
including a VEGFR2 and angiopoietin-1 receptor (TIE2) inhibitor) or cabozantinib (a VEGFR 
and hepatocyte growth factor receptor (MET) inhibitor). However, the fact that many agents 
in Phase III trials failed with non-biomarker enriched populations is currently being 
counteracted by a more precise approach. Primarily, Phase II proof-of-concept studies that 
test drugs blocking potential oncogenic addiction loops and Phase II and III studies using 
biomarker-based trial enrichment strategies to define activation of signalling pathways in 
HCC subgroups are currently on-going. For instance, genomic studies defined a human HCC 
subclass characterized by TGF-β signalling activation233 that is associated with an aggressive 
phenotype74. The small molecule galunisertib blocks TGF-β signalling and has been tested in 
Phase II as a single agent or in combination with sorafenib234. Similarly, overexpression 
and/or amplification of FGF19 is characteristic of 10-20% of cases of HCC65,66. New 
generation FGFR-specific kinase inhibitors have been tested in pre-clinical models 
demonstrating that FGF19 amplification is a predictive biomarker of response235. More 
recently, BLU9931, a highly specific FGFR-4 inhibitor, demonstrated pre-clinical activity in 
patient derived xenografts, providing the rationale for exploring this compound in phase I or 
II clinical trials236. Finally, universal activation of the RAS/MAPK axis is common in patients 
with advanced HCC237. First attempts to block this pathway with mitogen-activated protein 
kinase kinase (MEK) inhibitors (selumetinib) have failed in detecting significant objective 
radiological tumour responses238. The Assessing BAY86-9766 Plus Sorafenib for the 
Treatment of Liver Cancer (BASIL) trial tested refametinib (a MEK1-2 inhibitor) in advanced 
HCC, and results indicated that RAS mutations could be a potential biomarker of treatment 
response 239.  
 
Alternatively, recent data has emerged pointing towards biomarker-driven selection of 
candidates in testing drugs in Phase III trials. This has been the case for ramucirumab, which 
is currently in Phase III for second-line treatment of patients with advanced HCC and AFP > 
400 ng per mL, based on subgroups analysis data229. Similarly, tivantinib, a tubulin and MET 
inhibitor240, is currently being tested in Phase III only in MET-positive patients in a second-
line setting. Activation of MET is estimated to occur in approximately 50% of these patients. 
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A similar drug, cabozantinib , is being tested as a second-line therapy in an all-comers after 
preliminary positive effect in clinical studies241.  
 
Immune checkpoint inhibitors have been approved by regulatory agencies owing to their 
considerable activity in patients with advanced-stage melanoma and lung cancer242. The 
rationale for an immunological approach to treat HCC has been proposed for years. Indirect 
evidence includes the pivotal role that the immune system has in the development of 
chronic liver disease and HCC, dendritic cell-based approaches showing certain anti- tumour 
activity243,244 and occasional reports of cases of spontaneous remission. Although pilot 
studies with the cytotoxic T-lymphocyte protein 4 (CTLA-4) blocking antibody tremelimumab 
did not produce signals of efficay245, a recent phase I-II trial with the programmed cell death 
protein 1 (PD-1) inhibitor nivolumab showed a manageable adverse event profile and 
produced durable responses in patients with HCC patients who had tumours that were 
resistant to sorafenib246. Phase III trials have been designed to test this drug. Finally, two 
alternative types of molecular-based therapies are currently being explored in early clinical 
research studies: epigenetic modifying therapies247,248 and microRNAs249.  
Molecular targeted therapies are associated with acquired drug resistance. The most 
common traits of acquired resistance mechanisms are the persistent activation of the 
oncogenic target itself owing to secondary mutations — for example, mutation of EGFR 
(T790M) in gefitinib/erlotinib-resistant patients with non-small-cell lung cancer250 — or 
acquired mutations in alternative drivers of the pathway — such as mutations in genes 
encoding MAPKs in vemurafenib-resistant BRAF melanoma251. Acquired resistance to 
sorafenib in HCC has mostly been explored in experimental models. Several mechanisms 
have been implicated, including activation of MAPK14 signalling 68, enrichment of tumour-
initiating cells and re-activation of IGF/FGF signalling252. 
 
[H1] Quality of life 
 
Unsurprisingly, as liver disease and HCC tumour progresses quality of life (QOL) suffers. The 
purpose of measuring QOL should be to compare outcomes between treatment arms, even 
if one is a placebo. There is little agreement as to the best method of measuring QOL in HCC 
research. Although general instruments are in use, there are two that are specific to HCC. 
These are the European Organisation for Research and Treatment of Cancer Quality of Live 
Questionnaire (EORTC QLQ) 18253,254 and the Functional Assessment of Cancer Therapy-
Hepatobiliary (FACT-Hep)255 questionnaire. Both of these tools are derivatives of more 
general QOL questionnaires for cancer and have been validated externally, but there is little 
indication that they are measuring the same thing, or that they are comparable.  
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There is very little literature on QOL in HCC. Most studies report changes in QOL in single 
arm studies, and very few studies have designed primarily to compare two different 
treatments in patients with similar stage disease. For example, one study compared QOL 
after resection with QOL following radiofrequency ablation255. As expected, QOL was much 
better after radiofrequency ablation than after resection, and remained superior up to 36 
months post-treatment. In addition, QOL following radioembolization has been compared 
with TACE256. In this study, there was no overall difference in QOL between the two groups, 
but the sample size was small. Despite the lack of statistically significant differences, in the 
TACE group QOL was decreased at 2 and 4 weeks, whereas in the radioembolization group 
some aspects of QOL actually improved. However, in this study the patients who underwent 
radioembolization had more advanced disease than those who underwent TACE, so the 
results are not directly comparable. Finally, the SHARP trial demonstrating survival benefits 
of sorafenib compared to placebo also tested time-to-symptomatic progression — as 
measured by the Functional Assessment of Cancer Therapy–Hepatobiliary Symptom Index 8 
(FHSI8) — as co-primary end-point. The negative results of this end-point contrasted with 
the survival benefits obtained by sorafenib, thus challenging the accuracy the tool used19.  
 
[H1] Outlook  
[H2] Global disease burden 
 
The global burden of HCC is increasing and considerable challenges are ahead for improving 
the understanding and treatment of this complex disease. The main unmet medical needs 
for HCC are summarized in Box 1. Considering that HBV and HCV infection are the main risk 
factors for HCC development, it can be presumed that the implementation of new more 
effective anti-viral therapies might decrease the incidence of HCC on a global scale in the 
following decade. Antiviral therapies approved for HCV infection achieve sustained viral 
clearance in more than 90% of cases202,257, and well-established anti-HBV therapies lead to 
undetectable viral titres (circulating HBV-DNA) in most patients. Nonetheless, the fact that 
the risk factors can be eliminated (efficacy), does not always translate into global 
improvements (effectiveness) owing to suboptimal implementation of treatments in 
underdeveloped areas and other complex reasons. Similarly, despite that fact that 
surveillance is cost-effective in HCC, the global implementation of such programmes is still 
suboptimal and is estimated to engage <50% of the target population in the West. Public 
health policies encouraging the implementation of such programmes in well-defined 
populations should lead to an increase in early tumour detection, and hence survival 
benefits. Finally, in parallel with advances in the treatment of viral hepatitis, other 
aetiologies of HCC are emerging, particularly NASH-related HCC which is associated with 
obesity and diabetes. The effect of these unfolding risk factors on HCC burden remains to be 
elucidated, but might counterbalance the decreases expected with HCV control.  
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[H2] Drug and biomarker discovery 
 
High-throughput genomic studies reporting gene sequencing of large cohorts have already 
established the main oncogenic drivers of HCC. However, most of these drivers, such as the 
TERT promoter, TP53 and CTNNB1, have not proven to be druggable and as such 
understanding of their role in HCC has not translated into improving the management of the 
disease. Drug discovery targeting these complex proteins and regulatory mechanisms should 
represent a major breakthrough in HCC research258. On the other hand, the identification of 
driver mutations or amplifications in relevant genes — such as FGF19, CCND1 and VEGF — 
has not yet translated into proof-of-concept early clinical trials based on biomarkers. 
Understanding the targets of the microenvironment in tumour progression and response to 
therapies has been an area clearly underexplored79,231, considering the clinical relevance of 
this compartment in the risk of tumour development, prognosis and immunomodulation76–
79. In addition, despite results reporting preclinical testing of drugs in genetically modified 
models or patient-derived xenografts, clinically relevant models recapitulating the spectrum 
of human disease are still suboptimal.  
 
[H2] Disease management 
[H3] Standard therapy. 
 
Only five treatments are recommended by the European Association for the Study of the 
Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) guidelines 
for HCC management (Table 3; Figure 4)3,158,159. Several other treatments have been tested 
in RCTs since the last successful therapy (sorafenib) was approved, and all of these studies 
produced negative or inconclusive results. In early HCC, no adjuvant therapy has shown 
efficacy168 and this represents an important unmet medical need. In addition, since the 
advent of radiofrequency as the mainstream of local ablation, no other proposed approach, 
such as microwave, has led to a major control of the disease. Chembomebolization remains 
the sole proven effective therapy in intermediate HCC. None of the combination therapies 
with chemoembolization have shown additive outcome advantages. Phase III trials testing 
alternative therapies, such as radioemebolization, are awaited. Indications beyond 
guidelines for resection259 and TACE are widely applied in clinical practice, particularly in 
Asia260, and this represents an important challenge that needs to be addressed with robust 
and well-designed studies. 
 
[H3] Progress in treating advanced disease. 
 
Management of advanced HCC has attracted major attention during the past decade. Trials 
testing systemic chemotherapy have been almost abandoned and the few that were 
conducted showed disappointing results219. Sorafenib approval represented a breakthrough, 
27 
 
challenged the concept of advanced HCC as a cancer that is not druggable19 and paved the 
way for testing novel drugs. What has been unexpected is the failure of all molecular agents 
tested afterward sorafenib224–230. As a consequence, this major cause of cancer-related 
death remains as one of the few solid tumours with only one systemic therapy available. 
New avenues are currently being explored to overcome this situation. Among the drugs 
currently being tested in Phase II and Phase III trials (Table 4; Figure 5), some are exploring 
novel areas that led to major advancements in cancer management, such as immune 
checkpoint inhibition261. Others are targeting specific subpopulations of HCC patients based 
on biomarkers identified in phase I/II studies, such as tivantinib for MET-positive patients240, 
or ramucirumab for those patients progressing on sorafenib with an AFP of >400 ng per 
mL230. Finally, a few studies are exploring targeting specific tumour driver genes, which are 
those responsible for ‘oncogenic addiction’. Oncogene addiction is defined as the state of 
dependency of tumour cells on a given driver. Since solid tumours are expected to share 4-8 
drivers per tumour, the addiction to one specific oncogene confers status of primacy to this 
target262. Thus, clinically relevant anti-tumour responses are achieved when targeting those 
drivers, as is the case for inhibiting the effects of antiplastic lymphoma receptor tyrosine 
kinase (ALK) fusion rearrangement with crizotinib in patients with non-small-cell lung 
cancer263. Trial design in HCC should follow specific recommendations that are provided in 
Table 5.  
 
[H3] The future of precision medicine for HCC.  
HCC is one of the few cancers where non-invasive radiological criteria suffice for the 
diagnosis of the disease in patients with an underlying risk factor (cirrhosis)3,15. This clinical 
approach conflicts with the concept of precision medicine, which is based on the 
administration of selective therapies targeting molecular alterations relevant to tumour 
progression in a given individual. In order to implement precision medicine in HCC, a tumour 
biopsy is required and, as such, routine biopsy has now been adopted by guidelines for 
clinical trials in HCC research3. The reliability of this strategy is based on the assumption that 
one tumour biopsy suffices for recapitulating the molecular information found in the whole 
neoplasm. This concept is currently debatable in oncology owing to evidence of inter-
tumoural and intra-tumoural heterogeneity in all malignancies, including in HCC31,264. This 
observation prompts an important question: can we rely upon a single biopsy for decision-
making or should we obtain multiple biopsies, even though this more thorough approach 
appears clinically impractical?  
 
To explore heterogeneity we need to understand the concept of trunk, branch and 
passenger mutations31,265. Trunk mutations occur at the onset of the disease and are potent 
transforming drivers present in all cells of a given tumour at early stages31. Conversely, 
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branch mutations develop late in the natural history of the tumours or as result of acquired 
resistance under the pressure of therapies and thus are only present in a subgroup of 
tumour cells. Finally passenger mutations, the most common type of mutation, are of 
marginal relevance in terms of cell transformation, progression or dissemination, but they 
might be helpful in defining the clonality of tumours or their immunogenicity. Therefore, as 
reported in solid cancers such as non-small-cell cancer266, breast cancer and melanoma, 
molecular therapies that achieve good tumour response and survival benefits can do so by 
targeting trunk mutations that have been identified with a single biopsy. Conversely, 
heterogeneity might be cumbersome when branch mutations have a more dominant role, 
for instance at very advanced stages266 or in the setting of acquired resistance265. In these 
instances, liquid biopsy —checking either tumour DNA and mRNA in cell-free plasma or 
circulating tumour cells — emerges as the most promising alternative for the molecular 
monitoring of tumour progression and relapse267,268. Recent reports point to the benefits of 
liquid biopsy in recapitulating tissue trunk driver mutations269 and in capturing unique 
branch subclonal mutations acquired under treatment pressure270. Finally, heterogeneity has 
more important therapeutic implications for molecular agents than for immune check-point 
inhibitors.  
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Figure 1. The global burden of hepatocellular carcinoma. Incidence of hepatocellular 
carcinoma (HCC) according to data from Globocan 20121,3–9. ASR, Age-standardised rate per 
100,000 (Modified from10).  
Figure 2. Liver cancer incidence according to region and sex. Figures reflect age-
standardized rate per 100,000 inhabitants. (Adapted from1.)  
Figure 3. Cancer progression and driver genes. Major recurrent molecular defects observed 
early in liver carcinogenesis. TERT promoter mutations are common early events identified in 
most of HCC that develops in a cirrhotic liver. Other mechanisms are specifically related to 
risk factors: HBV and AAV2 viral infections induce insertional mutagenesis that recurrently 
targets oncogenes. Also, hepatocellular adenoma, a rare benign liver tumour occurring most 
frequently in women who take oral contraception, can transform into HCC with sequential 
accumulation of CTNNB1 and TERT promoter mutations with or without STAT3 activation33–
38. AAV2, adeno-associated virus 2; CCN, cyclin; CTNNB1, catenin β 1; FRK, fyn-related Src 
family tyrosine kinase; GNAS, GNAS complex locus; HBV, hepatitis B virus; HCA, 
hepatocellular adenoma; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HNF1A, 
HNF1 homeobox A; JAK1, Janus kinase 1; KMT2B (also called MLL4), lysine (K)-specific 
methyltransferase 4; IL6ST, interleukin 6 signal transducer; STAT3, signal transducer and 
activator of transcription 3 (acute-phase response factor); TERT, telomere reverse 
transcriptase. 
Figure 4: BCLC staging system and therapeutic strategy. Classification comprises five stages 
that select the best candidates for the best therapies currently available. Patients with 
asymptomatic early tumours (stages 0–A) are candidates for radical therapies (resection, 
transplantation or local ablation). Asymptomatic patients with multinodular HCC (stage B) 
are suitable for transcatheter arterial chemoembolization (TACE), whereas patients with 
advanced symptomatic tumours and/or an invasive tumoural pattern (stage C) are 
candidates to receive sorafenib. End-stage disease (stage D) includes patients with poor 
prognosis that should be treated by best supportive care. *Patients in Child-Pugh class C 
should be first considered for liver transplantation. **Treatment stage migration: Consider 
the next efficacious treatment in the algorithm when previous therapies fail. BCLC, 
Barcelona Clinic Liver Cancer; DDLT, deceased donor liver transplantation; EASL, European 
Association for the Study of Liver Disease; EORTC, European Organisation for Research and 
Treatment of Cancer; GRADE, grading of recommendations assessment, development and 
evaluation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; PEI, 
percutaneous ethanol injection; RF, radiofrequency ablation; TACE, transcatheter arterial 
chemoembolization; OS, overall survival; (Modified from3,158,159). 
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Figure 5. Molecular targeted therapies for HCC and their target signalling pathways. 
Summary of treatments tested in Phase II-III clinical trials. Orange receptors have tyrosine 
kinase activity and red receptors have serine/threonine kinase activity. Green boxes contain 
drugs with positive Phase III studies, red boxes contain drugs with negative results from 
Phase III trials and drugs in grey boxes have been tested in phase II studies. AA3R, adenosine 
A(3) receptor; AKT, protein kinase B; c-Kit, mast/stem cell growth factor receptor; AR, 
androgen receptor; CDK, cyclin dependent kinase; CTLA-4, cytotoxic T-lymphocyte protein 4; 
SDF1, stromal cell-derived factor 1; EGF, epidermal growth factor; EGFR, epidermal growth 
factor receptor; ERK, mitogen activated protein kinase kinase kinase; HDAC, histone 
deacetylase; HGF, hepatocyte growth factor;MEK, mitogen-activated protein kinase kinase; 
MET, hepatocyte growth factor receptor; mTOR, mammalian target of rapamycin; MYC, myc 
proto-oncogene protein; PD-1, programmed cell death protein 1; PD-L1, programmed cell 
death protein 1 ligand 1; PDGF, platelet-derived growth factor; PDGFR, platelet-derived 
growth factor receptor; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PLK1, 
serine/threonine-protein kinase PLK1; RAF, Raf family protein; RAS, Ras family protein; 
STAT3, signal transducer and activator of transcription 3; TAF, tumour-associated fibroblast; 
TAM: tumour-associated macrophage; TGFβ; transforming growth factor beta; TGFβR1, 
transforming growth factor beta receptor type-1; TIE2, angiopoietin-1 receptor; VEGF, 
vascular endothelial growth factor. 
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